Numerous clinical trials are always open and enrolling patients in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults 18 years of age and older who have or are at risk of developing cancer. The table below contains a list of all active clinical trials, with links to the educational and recruitment materials that are publicly available to patients and researchers.
The trials below are listed alphabetically by cancer type. To sort, hover over any of the column headings and click the up/down arrows. You can also search by keyword. To access the educational and recruitment material for a particular trial, click on the trial ID.
| Cancer Type | Trial ID/Educational Material | Target Patient Population |
|---|---|---|
| Various | EAQ202 | Ages 18-39 with any type of cancer except basal cell carcinoma |
| Various | EAQ222CD / CostCOM | Ages 18+ with any type of solid cancer of any stage |
| Various | EAQ223 / SUPPORT | Cancer patients at community-based treatment sites |
| Various | EAY191 / ComboMATCH | Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (advanced) |
| Various | EAY191-E5 / ComboMATCH-E5 | Metastatic (advanced) solid tumors with a KRAS G12C mutation |
| Bladder | EA8212 / BRIDGE | High risk; has not spread to the muscle |
| Blood | EA4231 | B-cell lymphoma (a type of non-Hodgkin lymphoma) |
| Blood | EA4232 / PTCL-STAT | Peripheral T-cell lymphoma (a type of non-Hodgkin lymphoma) |
| Blood | EA9181 | Acute lymphoblastic leukemia (ALL) |
| Blood | EA9213 | Acute lymphoblastic leukemia (ALL), T-cell Type |
| Blood | EAA173 / DETER-SMM | Smoldering myeloma |
| Blood | EAA181 / EQUATE | Myeloma, newly diagnosed |
| Blood | EAQ211 | Survivors of Hodgkin or non-Hodgkin lymphoma, age 15-39 when diagnosed |
| Blood | MM1OA-EA02 / myeloMATCH | Acute myeloid leukemia (AML) |
| Brain | Glioblastoma, newly diagnosed | |
| Breast | EA1151 / TMIST (Closed to Accrual) | Women planning for regular mammograms |
| Breast | EA1211 / DIRECT | Early stage, HER2 positive type |
| Breast | EAQ221CD / CONCURxP | Patients taking a CDK4/6 inhibitor |
| Colorectal | EA2222 / PUMP | Metastatic (advanced to the liver), not able to be removed by surgery (inoperable) |
| Esophagus | EA2174 | Locally advanced, able to be removed by surgery (operable) |
| Head and Neck | EA3132 | p53-mutated squamous cell type, after surgery |
| Head and Neck | EA3191 | Squamous cell carcinoma of the head and neck that has come back after initial therapy |
| Head and Neck | EA3211 | Metastatic (advanced) squamous cell carcinoma |
| Lung | EA5162 | Non-small cell type, metastatic (advanced) |
| Lung | EA5182 | Non-small cell type, metastatic (advanced) |
| Lung | EA5221 / ACHIEVE | Non-small cell type, metastatic (advanced) |
| Lung | EA5231 / CLEAR | Non-small cell type |
| Melanoma (Skin) | EA6141 | Metastatic (advanced) |
| Melanoma (Skin) | EA6192 / PET-Stop | Metastatic (advanced) |
| Pancreas | EA2185 | Patients with non-cancerous pancreas cysts |
| Pancreas | EA2192 / APOLLO | Has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation |
| Penis | EA8134 / InPACT | Spread to nearby tissue or lymph nodes (locally advanced) |
| Prostate | EA8191 / INDICATE | Has come back after surgery |
| Sarcoma | EA7211 / STRASS 2 | Able to be removed by surgery (operable); at high risk of returning |
| Sarcoma | EA7222 | Metastatic (advanced), not able to be removed by surgery |
| Throat | EA3161 | HPV positive type |
| Thyroid | Differentiated and BRAF V600E-mutated type that has spread after standard treatment | |
| Upper Urinary Tract | EA8192 | High grade (aggressive) |
